Pulmonary Rehabilitation During Chemotherapy in Stage IIIB/IV Small Cell Lung Cancer
Pulmonary Rehabilitation During Chemotherapy in Stage IIIB/IV Small Cell Lung Cancer: A Randomized Controlled Trial
This single-center, parallel-group randomized trial evaluated whether adding an 8-week physiotherapist-supervised pulmonary rehabilitation program to a home program improved functional exercise capacity, pulmonary function, and lung cancer symptoms in adults with stage IIIB/IV small cell lung cancer receiving chemotherapy. Thirty participants were randomized 1:1 to 9 scheduled face-to-face rehabilitation contacts plus twice-daily home exercise and comfortable-pace walking for 20 minutes per day, or to a home program of breathing exercises, coughing or huffing, and comfortable-pace walking for 20 minutes per day without face-to-face rehabilitation. Outcomes were assessed at baseline and after 8 weeks. The principal functional outcome for this report was change in 6-minute walk distance; spirometry and the 9-domain Lung Cancer Symptom Scale were exploratory outcomes.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
BACKGROUND: Patients with stage IIIB/IV small cell lung cancer receiving chemotherapy can experience deterioration in pulmonary function, exercise capacity, symptoms, and quality of life. Evidence for pulmonary rehabilitation during active chemotherapy remains limited.
STUDY DESIGN: Single-center, parallel-group, open-label randomized controlled trial conducted from November 2018 through May 2019.
SETTING: Oncology Department, Yeditepe University Hospital, Istanbul, Turkey.
ETHICS AND REGISTRATION: The Haliç University Ethics Committee approved the study (No. 109; October 30, 2018), and all participants provided written informed consent before enrollment. The trial was retrospectively registered on April 15, 2026.
PARTICIPANTS: Adults aged 18 years or older with stage IIIB/IV small cell lung cancer, Eastern Cooperative Oncology Group performance status 0-2, active chemotherapy, and no more than 3 completed chemotherapy cycles at enrollment. Participants had to understand the intervention instructions and provide written informed consent. Patients with stage I/II disease or a complication contraindicating pulmonary rehabilitation were excluded.
INTERVENTION GROUP: Nine scheduled face-to-face, physiotherapist-supervised contacts across 8 weeks were used to teach and monitor diaphragmatic and thoracic expansion exercises; postural drainage with percussion when indicated; active-cycle breathing, huffing, and effective coughing; upper- and lower-limb resistance exercises; and walking. The home program was prescribed twice daily, with comfortable-pace walking for 20 minutes per day.
CONTROL GROUP: An 8-week home program of diaphragmatic and thoracic breathing exercises, coughing or huffing, and comfortable-pace walking for 20 minutes per day. The control program did not include face-to-face pulmonary rehabilitation, resistance training, postural drainage or percussion, or active-cycle breathing.
OUTCOMES: Change in 6-minute walk distance from baseline to 8 weeks was designated the principal functional outcome for this report. Exploratory outcomes were forced vital capacity, forced expiratory volume in 1 second, FEV1/FVC, peak expiratory flow, forced expiratory flow at 25%-75% of forced vital capacity, and the 9-domain Lung Cancer Symptom Scale, assessed at baseline and after 8 weeks. No prospectively documented primary-secondary outcome hierarchy was located in the available source records.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Istanbul, Tyrkia (Türkiye)
- Yeditepe University Hospital, Oncology Department
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically confirmed small cell lung cancer, Stage IIIB or Stage IV
- Age 18 years or older
- Receiving active chemotherapy with no more than 3 completed chemotherapy cycles at enrollment
- Eastern Cooperative Oncology Group Performance Status 0, 1, or 2
- Able to understand the intervention instructions
- Written informed consent provided
Exclusion Criteria:
- Stage I or Stage II small cell lung cancer
- Any complication contraindicating pulmonary rehabilitation, including a pathological fracture, open wound, unstable cardiac disease, or active uncontrolled infection
- Inability or refusal to provide written informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Supervised Pulmonary Rehabilitation Plus Home Program
Eight-week program with 9 scheduled face-to-face, physiotherapist-supervised contacts. The contacts were used to teach and monitor diaphragmatic and thoracic expansion exercises; postural drainage with percussion when indicated; active-cycle breathing, huffing, and effective coughing; upper- and lower-limb resistance exercises; and walking. The prescribed home program was performed twice daily, with comfortable-pace walking for 20 minutes per day. |
Eight-week program with 9 scheduled face-to-face, physiotherapist-supervised contacts. The contacts were used to teach and monitor diaphragmatic and thoracic expansion exercises; postural drainage with percussion when indicated; active-cycle breathing, huffing, and effective coughing; upper- and lower-limb resistance exercises; and walking. The prescribed home program was performed twice daily, with comfortable-pace walking for 20 minutes per day. |
|
Aktiv komparator: Home Breathing, Coughing, and Walking Program
Eight-week home program consisting of diaphragmatic and thoracic breathing exercises, effective coughing or huffing, and comfortable-pace walking for 20 minutes per day. No face-to-face pulmonary rehabilitation, resistance training, postural drainage/percussion, or active-cycle breathing was provided. |
Eight-week home program consisting of diaphragmatic and thoracic breathing exercises, effective coughing or huffing, and comfortable-pace walking for 20 minutes per day. No face-to-face pulmonary rehabilitation, resistance training, postural drainage/percussion, or active-cycle breathing was provided. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in 6-Minute Walk Test Distance
Tidsramme: Baseline and Week 8
|
Functional exercise capacity measured as the distance walked in a 30-meter indoor corridor. Change is calculated as the Week 8 value minus the baseline value and is reported in meters. |
Baseline and Week 8
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Peak Expiratory Flow
Tidsramme: Baseline and Week 8
|
Peak expiratory flow measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters per second. |
Baseline and Week 8
|
|
Change in FEV1/FVC Ratio
Tidsramme: Baseline and Week 8
|
FEV1/FVC ratio measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in percentage points. |
Baseline and Week 8
|
|
Change in Lung Cancer Symptom Scale Domain Scores
Tidsramme: Baseline and Week 8
|
Nine Lung Cancer Symptom Scale visual analog domains were assessed: appetite, fatigue, cough, dyspnea, hemoptysis, pain, overall lung symptom burden, activities of daily living, and overall quality of life. Scores were recorded on 100-mm visual analog scales and reported on a 0-10 cm scale; lower scores indicate better status. Change is calculated as Week 8 minus baseline, so negative values indicate improvement. |
Baseline and Week 8
|
|
Change in Forced Expiratory Volume in 1 Second
Tidsramme: Baseline and Week 8
|
Forced expiratory volume in 1 second measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters. |
Baseline and Week 8
|
|
Change in Forced Vital Capacity
Tidsramme: Baseline and Week 8
|
Forced vital capacity measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters. |
Baseline and Week 8
|
|
Change in Forced Expiratory Flow at 25%-75% of Forced Vital Capacity
Tidsramme: Baseline and Week 8
|
Forced expiratory flow at 25%-75% of forced vital capacity measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters per second. |
Baseline and Week 8
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- HALIC-EC-109-2018
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
A de-identified analytic dataset, data dictionary, and reproducible statistical code may be made available by the corresponding author on reasonable request, subject to ethics, institutional, and consent constraints.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .